Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain.
For over a decade, until recently, it was thought that marijuana acts by activating brain-type cannabinoid receptors called CB1, and that a second type called CB2 cannabinoid receptor was found only in peripheral tissues. Neuronal CB2 receptors in the brain had been controversial. We reported the discovery and functional presence of CB2 cannabinoid receptors in the mammalian brain that may be involved in depression and drug abuse and this was supported by reports of identification of neuronal CB2 receptors that are involved in emesis. RT-PCR, immunoblotting, hippocampal cultures, immunohistochemistry, transmission electron microscopy, and stereotaxic techniques with behavioral assays were used to determine the functional expression of CB2 cannabinoid receptors in the rat brain and mouse brain exposed to chronic mild stress or treated with abused drugs. RT-PCR analyses supported the expression of brain CB2 receptor transcripts at levels much lower than those of CB1 receptors. In situ hybridization revealed CB2 mRNA in cerebellar neurons of wild-type but not of CB2 knockout mice. Abundant CB2 receptor immunoreactivity (iCB2) in neuronal and glial processes was detected in the brain. The effect of direct CB2 antisense oligonucleotide injection into the brain and treatment with JWH015 in motor function and plus-maze tests also demonstrated the functional presence of CB2 cannabinoid receptors in the central nervous system. In humans, there was a high incidence of Q63R polymorphism in the CB2 gene in Japanese alcoholics and depressed subjects. Contrary to the prevailing view that CB2 cannabinoid receptors are restricted to peripheral tissues and predominantly in immune cells, we demonstrated that CB2 cannabinoid receptors and their gene transcripts are widely distributed in the brain. This multifocal expression of iCB2 in the brain suggests that CB2 receptors may play broader roles than previously anticipated and may therefore be exploited as new targets in the treatment of depression and substance abuse.
Onaivi
Emmanuel S
ES
Department of Biology, William Paterson University, Wayne, NJ 07470, USA. Onaivie@wpunj.edu
D000818:Animals; D001522:Behavior, Animal / Q000502:physiology*; D001921:Brain / Q000033:anatomy & histology* / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007211:Indoles / Q000494:pharmacology; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D009474:Neurons / Q000378:metabolism / Q000648:ultrastructure; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D012333:RNA, Messenger / Q000096:biosynthesis; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000235:genetics / Q000378:metabolism* / Q000648:ultrastructure; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013239:Stereotyped Behavior / Q000187:drug effects; D013312:Stress, Physiological / Q000188:drug therapy; D013873:Thionucleotides / Q000627:therapeutic use
C469526:Cnr2 protein, rat; D007211:Indoles; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D043885:Receptor, Cannabinoid, CB2; D013873:Thionucleotides; C402944:JHW 015